Skip to content

Steve Garland

  • CEO/Founder
  • NQuiX Ltd
  • 10h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 446CitationsNumber of citations received by Steve's publications. Updated daily.

Other IDs

Research interests

GPCR Drug Discovery Protein-Protein Interactions Lead Generation Computational Chemistry Cheminformatics Chemogenomics

Co-authors (82)

  • David Gloriam

Publications (5)

  • The creation and characterisation of a National Compound Collection: the Royal Society of Chemistry pilot

    • Andrews D
    • Broad L
    • Fox D
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • Corrigendum to "(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors" [Bioorg. Med. Chem. Lett. 15 (2005) 3402-3406]

    • Bamford M
    • Alberti M
    • Bailey N
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • Errautm: (1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors" (Bioorg. Med. Chem. Lett. 15 (2005) 3402-3406 10.1016/j.bmcl.2005.05.021)

    • Bamford M
    • Alberti M
    • Bailey N
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Erratum: What is the potential of G protein-coupled receptor allosteric sites in drug design? (Future Medicinal Chemistry (2014) 6:7 (729-732))

    • Garland S
    N/AReaders
    0Citations
    Get full text
  • Seven transmembrane g protein-coupled receptors: Insights for drug design from structure and modeling

    • Barton N
    • Blaney F
    • Garland S
    • et al.
    N/AReaders
    8Citations

Professional experience

CEO/Founder

NQuiX Ltd

August 2011 - Present

Group Leader, Lead Generation

GlaxoSmithKline

December 2008 - August 2011(3 years)

Manager, 7TM Systems Modelling Group

GlaxoSmithKline

Computational Chemist

GlaxoSmithKline

RPR Research Fellow

University of Cambridge

Education history

PhD

University of Cambridge

BA (Hons)

Oxford University